Study of the drug acalabrutinib and rituximab in patients with CLL/SLL
Research Question:
Is the combination of the drug acalabrutinib and antibody therapy, rituximab, safe
and effective in patients who have previously untreated chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL)?
Basic Study Information
Purpose:
Despite an array of available therapies, chronic lymphocytic leukemia (CLL) remains
an incurable disease. The development of an improved therapy would be a major contribution
to the management of CLL and other B cell malignancies.
The investigator proposes that the drug acalabrutinib will work better combined with
high frequency low dose subcutaneous rituximab in the treatment of CLL.
Location: University of Rochester Medical Center
Study Reference #: ULYM18086
Lead Researcher (Principal Investigator)
Lead Researcher:
Paul Barr
Study Contact Information
Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search